3-N-succinimido-4-phenylthio-5-sulphamyl-benzoic acid methyl ester | 70730-01-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-N-succinimido-4-phenylthio-5-sulphamyl-benzoic acid methyl ester
• 英文别名: Methyl 3-(2,5-dioxopyrrolidin-1-yl)-4-phenylsulfanyl-5-sulfamoylbenzoate
• CAS: 70730-01-7
• 化学式: C₁₈H₁₆N₂O₆S₂
• 分子量: 420.467
• InChiKey: JXNIMKJZRCVCMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  158
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-N-succinimido-4-phenylthio-5-sulphamyl-benzoic acid methyl ester 、 三氟化硼 、 乙醚 、 硼氢化钠 、 二乙二醇二甲醚 以86%的产率得到
  参考文献：
  名称：

  MERKEL W.; MANIA D.; BORMANN D., LIEBIGS ANN. CHEM., 1979, NO 4, 461-469

  摘要：

  DOI：
• 作为产物：
  描述：

  甲醇 、 3-amino-4-phenylthio-5-sulphamyl-benzoic acid methyl ester 生成 3-N-succinimido-4-phenylthio-5-sulphamyl-benzoic acid methyl ester
  参考文献：
  名称：

  5-Sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent

  摘要：

  在4位被各种取代基取代的5-磺胺基苯甲酸和在3位被环状氨基团取代的具有利尿作用的磺胺二甲酸，以及它们的制造过程。

  公开号：

  US04010273A1

文献信息

• BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：Wanaski Stephen

  公开号：US20120004225A1

  公开（公告）日：2012-01-05

  The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特的类似物以及包含这些类似物的组合物。本发明还提供了含有这些丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特类似物的药物组合物以及它们的使用方法。所有这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾障碍、阿尔茨海默病、焦虑障碍、腹水、自闭症、躁郁症、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠、缺血、偏头痛、带前兆的偏头痛、神经痛、伤害性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合症。
• BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20150080350A1

  公开（公告）日：2015-03-19

  The present invention provides bumetanide, analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯酞、类似物和包含这些类似物的组合物。本发明还提供了含有这些丁苯酞、类似物的药物组合物以及它们的使用方法。这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾性障碍、阿尔茨海默病、焦虑症、腹水、自闭症、双相情感障碍、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠症、缺血、偏头痛、伴有先兆的偏头痛、神经痛、痛觉性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合征。
• BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20170246131A1

  公开（公告）日：2017-08-31

  The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor.
• US4010273A
  申请人：——

  公开号：US4010273A

  公开（公告）日：1977-03-01
• US4093735A
  申请人：——

  公开号：US4093735A

  公开（公告）日：1978-06-06